August 17, 2026 09:17 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
After SC rebuke, BCI chief apologises to NALSAR students over enrolment freeze row | Independence Day: PM Modi’s big youth pitch— AI training, free coaching amid exam row and job concerns | ‘Shakti Ki Saptadhara’: Modi reveals 7 pillars to power India’s next leap in his I-Day speech from Red Fort | West Bengal STF arrests 3 more suspected Pakistani spies in Cooch Behar | Bengal man arrested in Bengaluru over terror links, Afghanistan travel plan | Ajit Doval breaks silence on Operation Sindoor in Discovery’s explosive new docuseries | Rahul Gandhi's 'mock hug' taunt sparks row; Centre stresses 'mutual respect' with Italy | Delhi on high alert: Bomb threat to High Court, airport and multiple locations ahead of I-Day | ‘Who are they to interfere?’: CJI Surya Kant slams Bar Council of India over NALSAR students’ enrolment row | 'Shows how low Congress has sunk': BJP slams Rahul Gandhi over Modi foreign policy jibe
Coronavirus Vaccine

Adar Poonawalla thanks PM Modi for decisive 'policy changes and swift financial aid' amid vaccine shortage

| @indiablooms | Apr 21, 2021, at 07:18 am

Mumbai/IBNS: Serum Institute of India (SII) CEO Adar Poonawalla has lauded the Centre's policy change in vaccination, bringing all above 18 under the mass drive and extending financial support to the vaccine manufacturers.

SII which is manufacturing Covishied, developed by Oxford University and Swedish drug giant AstraZeneca, in India has been given Rs 3,000 crore as 100 per cent advance till July, reported NDTV citing senior sources in the Finance Ministry.

A similar advance of Rs 1,500 crore has been given to Hyderabad-based Bharat Biotech, the producer of indegenous Covaxin, the report added.

"This will ensure that the two companies get necessary funding to continue and scale up production," the sources said, the report added.

Earlier, Adar Poonawalla had appealed to the Centre for funds to scale up manufacturing amid high demand of the vaccine within and outside India.

Both Bharat Biotech and SII were facing shortage of funds "to scale up production, purchase raw materials, pay staff, and make and distribute enough doses of the vaccines", stated the report.

Poonawall, on Tuesday, tweeted in appreciation of the Centre's move.

The states can now buy coronavirus vaccine doses directly from manufacturers in the "liberalised and accelerated Phase 3 strategy of COVID-19 vaccination".

.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.